Lovaza was the competitor by Glaxo. It’s been a while, I had to look it up. Here’s a Forbe’s article to back up the nonsense that AMRN had to face. AMRN has to face the FDA again to expand label. It will be 6 years that heart patients with high triglycerides could have been on Vascepa. It may have prevented deaths. Unfortunately this is the situation in the drug market. It’s not fair but it’s the “rules” applied. Science eventually wins!

https://www.google.com/amp/s/www.forbes.com/s...lions/amp/